Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients.

TitleGroup M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients.
Publication TypePublication
Year of Publication2006
AuthorsBansal A, Gough E, Ritter D, Wilson C, Mulenga J, Allen S, Goepfert PA
JournalAIDS
Volume20
Issue3
Pagination353-60
Date Published2006 Feb 14
ISSN0269-9370
KeywordsAIDS Vaccines, Enzyme-Linked Immunosorbent Assay, Female, Genes, gag, HIV Infections, HIV-1, Humans, Immunity, Cellular, Male, T-Lymphocytes, United States, Zambia
Abstract

BACKGROUND: The enormous sequence diversity of HIV-1 has been a major obstacle in the development of a globally useful vaccine for AIDS. The consensus and ancestral sequence-based immunogens minimize the genetic distance between contemporary isolates and vaccine strains. Hence these sequences may be promising candidates for HIV vaccines or serve as a universal reagent set for evaluating Gag-specific responses.METHODS: In this study, we measured the T-cell reactivity to consensus (subtype A, B, C and group M), ancestral (group M and subtype B) and HXB2 Gag peptides (15-mers overlapping by 11) in HIV-1-infected subjects from two reference populations. We evaluated the Gag-specific T-cell responses in 43 chronically infected US (subtype B) and 13 Zambian (subtype C) subjects using an interferon-gamma enzyme-linked immunosorbent spot assay.RESULTS: Our findings demonstrate a broad cross-reactivity of nearly 70% among all the seven Gag immunogens evaluated. Consensus M sequences elicited similar levels of responses as did the consensus B, ancestral subtype B and HXB2 peptides in subtype B-infected US patients. In subtype C-infected Zambian subjects, responses of similar breadth and magnitude were elicited by consensus C, consensus M and ancestral M peptides.CONCLUSION: Our data demonstrate that peptide pools based on consensus or ancestral M-based sequences can be used to evaluate Gag-specific responses elicited by subtype B or subtype C-based immunogens.

DOI10.1097/01.aids.0000206501.16783.67
Alternate JournalAIDS
PubMed ID16439868
Grant ListU01 HD040533 / HD / NICHD NIH HHS / United States
R01 AI 49126 / AI / NIAID NIH HHS / United States
U01 HD040474 / HD / NICHD NIH HHS / United States
U19 AI 28147 / AI / NIAID NIH HHS / United States
U01 HD40533 / HD / NICHD NIH HHS / United States